Recipharm signs manufacturing deal with LobSor

LobSor is developing Lecigon, a treatment for advanced Parkinson’s disease currently at clinical stage.

Recipharm will manufacture the drug in its initial three years on the market. The company will help pay for development costs against a markup on manufacturing prices for a certain volume when Lecigon is produced for commercial sale.

The deal follows an earlier agreement where Recipharm developed and manufactured the Parkinson’s candidate for a recent clinical trial.

Recipharm executive vice president of development and technology Carl-Johan Spak said: "We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of Lecigon, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease."

LobSor Pharmaceuticals managing director Roger Bolsöy said: "Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the Lecigon project."

Last month, Recipharm signed an agreement with Israel-based RedHill Biopharma to manufacture its late-stage patented drug candidate, RHB-105, for treating Helicobacter pylori (H. pylori) bacterial infection.

Image: Recipharm executive vice president of development and technology Carl-Johan Spak. Photo: courtesy of Recipharm AB (publ).